Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
XCT
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "XCT" in MCE Product Catalog:
14
11
11 Cited Publications
Target:
Research Areas:
XCT-790 is a potent and selective inverse agonist for ERRα with an IC50 value of 0.37 μM. XCT-790 induces cell death in chemotherapeutic resistant cancer cells. XCT-790 (Compound 12) is inactive against ERRγ and the estrogen receptors ERα and ERβ .
10
Target:
Ferroptosis Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) Glutathione Peroxidase ACSL Family Keap1-Nrf2 Heme Oxygenase (HO)
Research Areas:
Cardiovascular Disease Neurological Disease Metabolic Disease
UAMC-3203 (FXT-001) is a potent ferroptosis inhibitor with an IC50 of 12 nM. UAMC-3203 inhibits NLRP3 inflammasome activation and reactive oxygen species (ROS) production, maintains intracellular glutathione, and acts as a radical-trapping antioxidant in lipid bilayers. UAMC-3203 promotes NRF2/HO-1 antioxidant signaling while restoring GPX4 and xCT and inhibiting ACSL4. UAMC-3203 can be used in research on diabetic peripheral neuropathy, post-stroke cognitive impairment, atherosclerosis, corneal epithelial injury, spinal cord injury, acute iron poisoning, and aortic dissection .
10
10 Cited Publications
Synonyms: FXT-001 hydrochloride
Target:
Ferroptosis Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) Glutathione Peroxidase ACSL Family Keap1-Nrf2 Heme Oxygenase (HO)
Research Areas:
Cardiovascular Disease Neurological Disease Metabolic Disease
UAMC-3203 (FXT-001) hydrochloride is a potent ferroptosis inhibitor with an IC50 of 12 nM. UAMC-3203 hydrochloride inhibits NLRP3 inflammasome activation and reactive oxygen species (ROS) production, maintains intracellular glutathione, and acts as a radical-trapping antioxidant in lipid bilayers. UAMC-3203 hydrochloride promotes NRF2/HO-1 antioxidant signaling while restoring GPX4 and xCT and inhibiting ACSL4. UAMC-3203 hydrochloride can be used in research on diabetic peripheral neuropathy, post-stroke cognitive impairment, atherosclerosis, corneal epithelial injury, spinal cord injury, acute iron poisoning, and aortic dissection .
1
1 Cited Publications
Cat. No.: HY-P702444
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: SLC7A11; Cystine/Glutamate Transporter; Solute Carrier Family 7 Member 11; Solute Carrier Family 7, (Cationic Amino Acid Transporter, Y+ System) Member 11; XCT; Uncharacterized Protein SLC7A11; Solute Carrier Family 7 (Anionic Amino Acid Transporter Light
Species:
Human
Source:
E. coli Cell-free
1
SLC7A11-IN-1 is a potent solute carrier family 7 member 11 (SLC7A11, xCT) inhibitor. SLC7A11-IN-1 shows antiproliferative activity. SLC7A11-IN-1 inhibits cell invasion and metastasis. SLC7A11-IN-1 induces Apoptosis and cell cycle arrest at S-phase. SLC7A11-IN-1 shows anti-tumor activity .
Cat. No.: HY-RS13325
Target:
Research Areas:
SLC7A11 Human Pre-designed siRNA Set A contains three designed siRNAs for SLC7A11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-169056
CAS No.: 14668-59-8
Target:
Research Areas:
SLC7A11-IN-2 (Compound 1) is an SLC7A11/xCT inhibitor. SLC7A11-IN-2 induces cell death in HeLa cells by lowering intracellular glutathione levels and increasing oxidative stress, thereby disrupting the oxidative balance within the cells, with an IC50 value of 10.23 μM. Molecular dynamics simulation analysis indicates that SLC7A11-IN-2 has a stronger binding affinity to SLC7A11 compared to Erastin (HY-15763). SLC7A11-IN-2 can be utilized in research within the field of cervical cancer .
Cat. No.: HY-P990610
Cat. No.: HY-RS16551
Target:
Research Areas:
Slc7a11 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Slc7a11 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-119612
CAS No.: 300837-31-4
Synonyms: XCT
Research Areas:
XCT0135908 (XCT) is a selective Nurr1-RXRα activator with an EC50 value of 0.3 μM in human dopaminergic SH-SY5Y cells. XCT0135908 protects dopaminergic cells against the Parkinson’s disease-related toxin MPP +. XCT0135908 can be used for the research of Parkinson’s disease .
Cat. No.: HY-10426R
CAS No.: 725247-18-7
Research Areas:
XCT790 (Standard) is the analytical standard of XCT790 (HY-10426). This product is intended for research and analytical applications. XCT-790 is a potent and selective inverse agonist for ERRα with an IC50 value of 0.37 μM. XCT-790 induces cell death in chemotherapeutic resistant cancer cells. XCT-790 (Compound 12) is inactive against ERRγ and the estrogen receptors ERα and ERβ .
Cat. No.: HY-162963
CAS No.: 2982696-04-6
Synonyms: PPARδ agonist 11
Research Areas:
DN203316 (PPARδ agonist 11) is a potent, selective, orally active PPARδ agonist (EC50 = 20 nM) with high selectivity over PPARα and PPARγ. DN203316 suppresses NF-κB-mediated inflammatory signaling, inhibits ferroptosis by upregulating xCT and GPX4, and attenuates STING-TBK1-IRF3-driven fibrogenic responses. DN203316 is useful for research on inflammatory disorders, metabolic dysfunction-associated steatohepatitis (MASH), and liver fibrosis .
Category:
Cat. No.: HY-179481
CAS No.: 3085517-19-4
Research Areas:
Ferroptosis inducer-13 is a 5′-prenylated chalcone derivative that effectively induces ferroptosis in human non-small cell lung cancer (NSCLC) cells by altering the activity of the Nrf2/xCT/GPX4 pathway. Ferroptosis inducer-13 exhibits potent anti-proliferative effects in vitro, and inhibits tumour growth in a NSCLC mouse model. Ferroptosis inducer-13 can be used for NSCLC research .
Cat. No.: HY-182601
CAS No.: 1639784-02-3
Target:
Research Areas:
MC-100093 is an orally active, blood-brain barrier-permeable GLT-1 expression upregulator . MC-100093 upregulates the expression of GLT-1 and xCT in rats, and alleviates sedative agent-induced GLT-1 downregulation, IL-6 upregulation and motor hyperactivity. MC-100093 upregulates GLT-1 expression and enhances glutamate uptake in astrocyte-neuron co-culture systems. MC-100093 reduces ethanol consumption and preference, and exerts gender-specific antidepressant-like effects . MC-100093 can be used in studies related to sedative agent overdose, mood disorders and alcohol use disorders .
Cat. No.: HY-182055
Target:
Research Areas:
Anticancer agent 309 (Compound HZ-1) is an anticancer agent and G-quadruplex binder, with Kd values of 2.46 μM and 1.61 μM for c-Myc G4 and KRAS G4, respectively. Anticancer agent 309 promotes the formation of intranuclear G4. Anticancer agent 309 shows higher selectivity for parallel G4 than for non-parallel G4. Anticancer agent 309 inhibits the NRF2 signaling pathway and reduces the expression of XCT and GPX4. Anticancer agent 309 induces Ferroptosis, Apoptosis and immunogenic cell death in cells. Anticancer agent 309 exerts antitumor efficacy against breast cancer. Anticancer agent 309 is applicable for the research of breast cancer .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
